Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SG301 in Hematological Malignancies
NCT04684108Phase 1Active, not recruiting
- Sponsor
- Shangjian Bio
- Start
- Nov 2021
- Primary completion
- Jun 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SG301 in multiple myeloma (MM) and hematological malignancy, sponsored by Shangjian Bio. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 1 year and Maximum Tolerated Dose / Maximum Administered Dose / Recommended Phase 2 Dose at 1 year. Started Nov 2021; status: active, not recruiting.
02
Drugs
SG301
03
Conditions
multiple myeloma (MM)hematological malignancy
Beyond the preview
Go deeper on NCT04684108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04684108.